Chimerix, Inc.: Series E $16M

Posted in I - Series E, Q - 3Q09, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

Oct

2009

Liquidia, Inc.: Series C $7M

Posted in I - Series C, Q - 3Q09, R - SOUTH EAST, X - Device (Delivery), XX - NC

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $7M Series C financing. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates and Firelake Capital.

Aug

2009

Viamet Pharmaceuticals, Inc.: Series B $18M

Posted in I - Series B, Q - 3Q09, R - SOUTH EAST, X - Inhibitor (Metalloenzyme), XX - NC

Viamet Pharmaceuticals (Morrisville, NC) a pre-clinical stage pharmaceutical company focused on small-molecule inhibitors of metalloenzymes, closed a $18M Series B financing. Participants include Novartis Option Fund. Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.

Jul

2009

CeNeRx BioPharma, Inc.: Series C $4M

Posted in I - Series C, Q - 2Q09, R - SOUTH EAST, X - CNS, XX - NC

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

May

2009

Cempra Pharmaceuticals, Inc.: Series C $46M

Posted in I - Series C, Q - 2Q09, R - SOUTH EAST, X - Antibacterial, XX - NC

Cempra Pharmaceuticals (Chapel Hill, NC) a clinical-stage company developing antibiotics for difficult-to-treat and drug-resistant infections, closed a $46M Series C financing. Participants include Quaker BioVentures, Devon Park Bioventures, Aisling Capital, Intersouth Partners, Teachers’ Private Capital and I. Wistar Morris III.

May

2009

nContact Surgical, Inc.: Series C $15M

Posted in I - Series D, Q - 2Q09, R - SOUTH EAST, X - Device (Cardiology), XX - NC

nContact Surgical (Morrisville, NC) a development-stage company focused on a cardiac tissue coagulation device intended to treat atrial fibrillation epicardially on a beating heart, closed a $15M Series C financing. Participants include Tall Oaks Capital, Village Ventures, Finistere Partners, Intersouth Partners, Massey Burch Capital, Harbert Venture Partners and Hippo Ventures.
CORRECTION | Previously reported as [...]

May

2009

Piedmont Pharmaceuticals, LLC: Series C $5M

Posted in I - Series C, Q - 2Q09, R - SOUTH EAST, X - Lice, X - Parasitology, X - Veterinary, XX - NC

Piedmont Pharmaceuticals (Greensboro, NC) a commercial-stage specialty pharma company focused on parasitology and drug delivery systems for human and companion animal use, closed a $5M Series C financing. Participants include CM Capital.

Feb

2009

Diagnosoft, Inc.: Series B $4M

Posted in I - Series B, Q - 1Q09, R - SOUTH EAST, X - Device (Imaging), XX - NC

Diagnosoft (Morrisville, NC) an early-stage device company focused on analyzing MRI images of the heart to measure and visualize cardiac muscle function, closed a $4M Series B financing. Participants include Technology Development Fund.

Next Entries »

to top of page...